Abstracts tagged "anti-TNF therapy"

Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Douglas C. Wolf¹, Martha Skup², Hongbo Yang³, Elizabeth Faust³, Jenny Griffith², Jingdong Chao² and Mark Lebwohl⁴, ¹Atlanta Gastroenterology Associates, Atlanta, GA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Mount Sinai Medical Center, New York, NY
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
Abstract Number: 975 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Inhibition on Radiographic Progression in Ankylosing Spondylitis: An Observational Cohort Study of 374 Patients
Walter Maksymowych¹, Yufei Zheng², Stephanie Wichuk¹, Sasha Bernatsky³, Praveena Chiowchanwisawakit⁴ and Robert G Lambert⁵, ¹Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ²Alberta Institute of Health Economics, Edmonton, AB, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Radiology, Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: An analysis of radiographic progression in an observational cohort has suggested that anti-TNF therapy lessens radiographic progression, especially when treatment is introduced within 5…
Abstract Number: 1741 • 2015 ACR/ARHP Annual Meeting
Abdominal Fat Mass Assessment in Recent Onset Spondyloarthritis: Data from the DESIR Cohort
Hélène Che¹, Adrien Etcheto², Camille Souffir³, Sami Kolta⁴, Pascal Richette⁵, Anna Molto⁶, Maxime Dougados², Christian Roux⁴ and Karine Briot⁴, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Service de rhumatologie, Hopital Cochin, Paris, France, ⁴Rheumatology B Department, Hôpital Cochin, Paris, France, ⁵Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ⁶Hopital Cochin, Paris Descartes University, Paris, France
Background/Purpose: Studies have shown a strong prevalence of cardiovascular events among patients with spondyloarthritis (SpA). Recent studies indicate that visceral adipose tissue (VAT) is highly…
Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Antonio Marchesoni⁵, Roberta Ramonda⁶, Florenzo Iannone⁷, Roberto Gorla⁸, Elisa Gremese⁹, Marcello Govoni¹⁰, Pier Carlo Sarzi-Puttini¹¹, Gianfranco Ferraccioli¹², Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, ⁶Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ⁹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ¹⁰Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ¹¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ¹²Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of rheumatoid arthritis (RA) and…
Abstract Number: 556 • 2015 ACR/ARHP Annual Meeting
Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy
Sharzad Emamikia¹, Elizabeth V. Arkema², Noémi Györi¹, Jacqueline Detert³, Katerina Chatzidionysiou¹, Maxime Dougados⁴, Gerd Burmester⁵ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The goal of rheumatoid arthritis (RA) treatment is remission or, when not achievable, low-disease-activity (LDA). Initial combined therapy with MTX + anti-TNF achieves these…
Abstract Number: 1042 • 2015 ACR/ARHP Annual Meeting
Pragmatic Multicenter Open-Label Randomized Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands
Marjan Ghiti Moghadam¹, Harald E. Vonkeman², Peter M. ten Klooster³, Janneke Tekstra⁴, Dirkjan van Schaardenburg⁵, Mirian Starmans-kool^6,7, Elisabeth Brouwer⁸, Reinhard Bos⁹, Willem F. Lems¹⁰, Edgar Colin¹¹, Cornelia F. Allaart¹², Inger L. Meek¹³, Robert B.M. Landewé¹⁴, Hein J. Bernelot Moens¹⁵, Piet van Riel¹³, Mart A.F.J. van de Laar¹⁶, Tim Jansen¹⁷ and on behalf of the Dutch National POET Collaboration., ¹rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Rheumatology, Atrium Medical center, Heerlen, Netherlands, ⁸Rheumatology, University Medical center Groningen, Groningen, Netherlands, ⁹Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹²Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, ¹³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹⁵rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: TNF-inhibitors (TNFi) are effective treatments of rheumatoid arthritis (RA). It is not clear if patients in remission or stable low disease activity need to…
Abstract Number: 1989 • 2015 ACR/ARHP Annual Meeting
Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients
Montserrat Santos-Gómez¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Santos Castañeda³, Norberto Ortego-Centeno⁴, M. Enriqueta Peiró¹, Paz Collado⁵, Sheila Melchor⁶, Antonio Mera⁷, Eva Pérez-Pampin⁸, Esteban Rubio Romero⁹, Jaime Calvo-Alen¹⁰, Elena Aurrecoechea¹¹, Iñigo Rúa-Figueroa¹², Mauricio Minguez¹³, Gabriel Herrero-Beaumont¹⁴, Beatriz Bravo¹⁵, José Rosas¹⁶, Javier Narváez¹⁷, Javier Calvo¹⁸, Rafael Ariza-Ariza¹⁹, Mercedes Freire²⁰, Pablo Lluch Mesquida²¹, Cristina Mata²², Eva Galindez-Agirregoikoa²³, Juan María Blanco Madrigal²³, Amalia Sánchez²⁴, José Salvatierra²⁵, Vanesa Calvo-Río¹, Carmen Gonzalez-Vela²⁶, Natalia Palmou¹, Leyre Riancho-Zarrabeitia¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain, ⁴Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ⁵Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario de Santiago de Compostela, La Coruña, Spain, ⁸Rheumatology, Hospital Universitario de Santiago de Compostela, La coruña, Spain, ⁹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Rheumatology Division, Hospital de Sierrallana, Torrelavega, Spain, ¹¹Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹²Rheumatology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canarias, Spain, ¹³Department of Rheumatology, Hospital Universitario San Juan, Alicante, Spain, ¹⁴Department of Osteoarticular Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹⁵Pediatric rheumatology, Hospital Virgen de las Nieves, Granada, Spain, ¹⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁸Rheumatology, Hospital General Consorcio de Valencia, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁰Rheumatology, Complejo Hospitalario Universitario de A Coruña, La Coruna, Spain, ²¹Hospital Mateu Orfila, Mahón (Menorca), Spain, ²²Rheumatology, Hospital de Sierrallana, Laredo, Spain, ²³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Hospital Lucus Augusti, Lugo, Spain, ²⁵Hospital Universitario de San Cecilio, Granada, Spain, ²⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Aortitis is often refractory to conventional immunosuppressive (IS) therapy. The use of biological therapy, such as tocilizumab (TCZ) and anti-TNFα agents have been…
Abstract Number: 2854 • 2015 ACR/ARHP Annual Meeting
Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Désirée van der Heijde¹, Maxime Dougados², Walter Maksymowych³, Gina Bergman⁴, Sean P. Curtis⁴, Anjela Tzontcheva⁴, George Philip⁴, Susan Huyck⁴ and Joachim Sieper⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Paris-Descartes University, Paris, France, ³University of Alberta, Edmonton, AB, Canada, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: The tolerability and efficacy of golimumab (GLM) as a treatment for nonradiographic axial spondyloarthritis (nr-axSpA) were recently investigated in a randomized, double-blind (DB), placebo…
Abstract Number: 557 • 2015 ACR/ARHP Annual Meeting
Early Intensification of Treatment Induces Superior Outcomes in Two Randomized Trials According to Predicted Vs. Observed Radiographic Progression in Rheumatoid Arthritis
Adrian Levitsky¹, Marius C. Wick², Timo Möttönen³, Marjatta Leirisalo-Repo⁴, Leena Laasonen⁵, Hannu Kautiainen^6,7, Markku Korpela⁸, Ronald F. van Vollenhoven¹ and Vappu Rantalaiho⁸, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Radiology, Karolinska University Hospital, Stockholm, Sweden, ³Internal Medicine, Division of Rheumatology, Turku University Central Hospital, Turku, Finland, ⁴Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁵Helsinki Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁶Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁷Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ⁸Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
Background/Purpose: Predicted vs. Observed Radiographic Progression in early Rheumatoid Arthritis (POPeRA) is a method that has previously confirmed the relative radiographic efficacy of synthetic disease-modifying…
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 2057 • 2015 ACR/ARHP Annual Meeting
Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Begoña Ruiz-Argüello¹, Ainara Maguregui¹, Ainhoa Ruiz del Agua¹, Dora Pascual-Salcedo², Ana Martínez², Teresa Jurado³, Chamaida Plasencia⁴, Alejandro Balsa⁵, Francisca Llinares-Tello⁶, José Rosas⁷, Nerea Torres¹, Antonio Martínez¹ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁶Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Infliximab (IFX) is the most immunogenic of anti-TNFα drugs available to treat patients with rheumatic diseases. The recent approval of the first infliximab biosimilars in…
Abstract Number: 2859 • 2015 ACR/ARHP Annual Meeting
Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis
Atul A. Deodhar¹, Joachim Sieper², Owen Davies³, Tommi Nurminen⁴ and Philip J. Mease⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²University Hospital Charité, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Recent studies suggest that patients' (pts') body weight impacts response to anti-TNF treatment in pts with spondyloarthropathies1 including axial spondyloarthritis (axSpA).2 Here we investigate…
Abstract Number: 578 • 2015 ACR/ARHP Annual Meeting
Study of the Production of Antinuclear Antibodies and Anti-Ds DNA Antibodies in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Ran Matsudaira^1,2, Naoto Tamura³, Yoshichika Sugisaki², Tomoko Ito⁴, Kentaro Minowa², Michihiro Ogasawara², Ken Yamaji², Yoshinori Kanai¹, Kenjiro Yamanaka¹ and Yoshinari Takasaki², ¹Division of Internal Medicine and Rheumatology, Sasaki institute Kyoundo Hospital, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University, School of Medicine, Tokyo, Japan, ³Department of Internal Medicien and Rheumatology, Juntendo University, School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: The production of autoantibodies, such as anti-nuclear antibodies (ANA) and anti-ds DNA antibodies (anti-DNA), is commonly observed in patients who have been treated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].